Seagen, A Wholly Owned Subsidiary Of Pfizer

This study tests a combination of two drugs—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and shrinks tumors. About 172 adults will take part. This is not a cure; it aims …

This early-stage trial tests a new drug called sigvotatug vedotin, alone or with other cancer treatments, in people with advanced solid tumors like lung, head and neck, and breast cancer. The main goal is to check safety and find the right dose. Around 1,000 participants will be …

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, alone or with pembrolizumab in people with advanced solid tumors (like lung, head and neck, or breast cancer) that have spread or can't be removed. The main goals are to find a safe dose and check for side effects. A…

This study tests a drug called disitamab vedotin, alone or with pembrolizumab, in people with advanced bladder cancer that has a protein called HER2. The goal is to see if the drug shrinks tumors and how safe it is. About 372 adults whose cancer has spread or cannot be removed wi…

This study tests whether adding tucatinib and trastuzumab to standard chemotherapy helps people with HER2-positive colorectal cancer that has spread or can't be removed. About 400 participants will be randomly assigned to the new combo or standard treatment. The goal is to see if…